Cargando…
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
Asthma is a heterogeneous respiratory disease characterized by usually reversible bronchial obstruction, which is clinically expressed by different phenotypes driven by complex pathobiological mechanisms (endotypes). In recent years several molecular effectors and signaling pathways have emerged as...
Autor principal: | Cheng, Shih-Lung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399988/ https://www.ncbi.nlm.nih.gov/pubmed/34440488 http://dx.doi.org/10.3390/life11080744 |
Ejemplares similares
-
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021) -
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023) -
The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022) -
Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022) -
Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
por: Plaza, Vicente, et al.
Publicado: (2023)